The top 5 OncLive TV videos of the week.
News|Articles|February 10, 2026
- Vol.27/No.4
- Volume 27
- Issue 4
FDA Guidance Signals Shift Toward MRD-Driven Accelerated Approvals in Multiple Myeloma
Author(s)Chris Ryan
Fact checked by: Jax DiEugenio, Ron Panarotti
Experts break down the FDA’s draft guidance on the use of MRD end points to support accelerated drug approvals in multiple myeloma.
Advertisement
Advertisement
More than 20 new drugs or biological products have been approved for the treatment of multiple myeloma since 2003, translating to improved response rates and long-term outcomes across the treatment continuum.1 However, the integration of novel treatment strategies and combinations has added complexity to trials evaluating newer drugs and treatments, with longer-term follow-up required to properly assess end points such as progression-free survival (PFS) and overall survival (OS).
Related to this article
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Iberdomide plus daratumumab/dexamethasone improved PFS vs DVd in relapsed/refractory multiple myeloma, meeting a dual primary end point of EXCALIBER-RRMM.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Most patients treated with talquetamab at a single center would not have qualified for MonumenTAL-1, yet responses were similar regardless of trial eligibility.
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Advertisement
Advertisement